OTC Watch

All stocks / OTLC

Oncotelic Therapeutics, Inc. OTLC

Oncotelic Therapeutics (OTLC): convertible notes mentioned in an 8-K in August 2026, a late 10-K notice in March 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated floatCostly financingLate filing OTCQBCalifornia, USA
Live quote on OTC Markets

Market listing

Full name
ONCOTELIC THERAPEUTICS INC
Market tier
OTCQB
Trading status
Active
Last trade
Nov 16
Source: Stockwatch, 2026-11-17

News headlines

Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature
2026-10-26 08:00 · News Release
Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discovery
2026-10-20 08:00 · News Release
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
2026-10-05 08:00 · News Release
Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th
2026-08-03 08:35 · News Release
Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle(TM) Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)
2026-07-22 09:30 · News Release
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
2026-07-07 09:30 · News Release
Oncotelic Announces Peer-Reviewed Validation of Deciparticle(TM) Platform Supporting Clinical Development of Sapu003
2026-06-29 08:30 · News Release
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
2026-06-18 08:00 · News Release
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
2026-06-17 08:00 · News Release
Oncotelic Showcases PDAOAI(TM) Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote
2026-06-08 08:00 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net income
$249,279,832
What it means

It earned more than it spent

Steady

After all costs, the company kept $249.3 million as profit in the year.

The report says
Cash and cash equivalents
$88,857
Net cash used in operating activities
($1,383,145)
What it means

The cash could run out soon

Under strain

It had $88,857 in the bank and used about $115,262 a month. At that pace the money lasts less than a month unless it borrows or sells more shares.

The report says
Total assets
$393,088,242
Total liabilities
$131,356,683
What it means

It owns more than it owes

Steady

Everything the company owns adds up to $393.1 million. Its debts and unpaid bills add up to $131.4 million. That is about $0.33 owed for every $1 owned.

What this adds up to

1 of 3 checks show strain. The cash could run out soon. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-13

Estimated float about 361,652,650 shares as of 2026-11-13: 457,512,796 outstanding minus 95,860,146 held by 2 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Costly financing2026-08-04

8-K filed 2026-08-04 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2026-06-29

8-K filed 2026-06-29 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Late filing2026-03-31

Filed NT 10-K on 2026-03-31: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Costly financing2026-01-29

8-K filed 2026-01-29 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2026-01-07

8-K filed 2026-01-07 mentions: equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2026-01-06

8-K filed 2026-01-06 mentions: equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Shares outstanding

Source: SEC filings
2025-12-31
442.6M
2026-03-31
444.2M
2026-04-14
444.2M
2026-05-14
444.5M
2026-06-30
457.0M
2026-08-13
457.5M
2026-09-30
457.5M
2026-11-13
457.5M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 10-Q10-Q
2026-10-30 44
2026-10-26 8-K8-K
2026-10-13 8-K8-K
2026-08-13 10-Q10-Q
2026-08-04 8-K8-K
2026-07-23 44
2026-07-22 D
2026-07-21 44
2026-07-14 44
2026-07-14 44
2026-07-14 44

Common questions about OTLC

Does OTLC file reports with the SEC?

Yes. Oncotelic Therapeutics files with the SEC under company number 0000908259. The most recent filing we hold is a 10-Q dated 2026-11-16.

Source record

How many OTLC shares are outstanding?

457,512,796 shares as of 2026-11-13, as reported to the SEC.

Source record

Has OTLC filed reports late?

Yes. In the last 12 months it filed 1 late-filing notice, most recently a NT 10-K on 2026-03-31. A notice means a report was not ready on time; check whether the report followed.

Source record

Who runs Oncotelic Therapeutics?

Officers named in its insider filings: Seymour Howard Fein (CRO/CMO), Anthony E Maida Iii (DIRECTOR AND CMO - TRANS. MED.) and Saran Saund (CBO).

Source record

Is Oncotelic Therapeutics making money?

After all costs, the company kept $249.3 million as profit in the year. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record